Stocks and Investing
Stocks and Investing
Mon, April 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BLUE) at Hold with Decreased Target to $36 on, Apr 19th, 2021
Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $45 to $36 on, Apr 19th, 2021.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Cory Kasimov of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $39 on, Wednesday, February 17th, 2021
These are the ratings of the 2 analyists that currently disagree with Matthew
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $72 on, Monday, March 29th, 2021
- Difei Yang of "Mizuho" Upgraded from Hold to Strong Buy and Increased Target to $69 on, Wednesday, March 10th, 2021
Contributing Sources